Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company PLC    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC (PRGO)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Perrigo : to Present at the Stifel 2017 Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:22pm CEST

DUBLIN, Nov. 10, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Stifel Healthcare Conference at 8:45 AM EST on Tuesday, November 14, 2017. Interested parties can access the presentation webcast at http://perrigo.investorroom.com/events-webcasts.

About Perrigo

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products(®). Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world's largest manufacturers of over-the-counter ("OTC") healthcare products and suppliers of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; resolution of uncertain tax positions; the impact of U.S. tax reform legislation; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; the Company's ability to achieve its guidance; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives. In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content with multimedia:http://www.prnewswire.com/news-releases/perrigo-company-to-present-at-the-stifel-2017-healthcare-conference-300553950.html

SOURCE Perrigo Company plc


© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PERRIGO COMPANY PLC
10/15PERRIGO : Announces The Launch Of An AB Rated Generic Version Of Androgel® Topic..
PR
10/11PERRIGO : appoints new CEO
AQ
10/10PERRIGO : Initial filing by director officer or owner of more than ten percent.
PU
10/09PERRIGO CO PLC : Change in Directors or Principal Officers, Financial Statements..
AQ
10/09Perrigo replaces CEO Roehrhoff with consumer goods veteran
RE
10/09PERRIGO : Drugmaker Perrigo Hires a New CEO -- Update
DJ
10/08PERRIGO : Appoints Murray S. Kessler As President And Chief Executive Officer In..
PR
10/03PERRIGO : Confirms Patent Challenge for Generic Version of Jublia Topical Soluti..
AQ
10/02PERRIGO : Announces Patent Litigation Settlement for the Generic Version of Pica..
AQ
10/01PERRIGO : Confirms Patent Challenge for Generic Version of Jublia® Topical Solut..
PR
More news
News from SeekingAlpha
08:28a10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targe.. 
10/09FDA issues new guidance for developers of complex generics 
10/09All Eyes On Treasuries (Wall Street Breakfast Podcast) 
10/09WALL STREET BREAKFAST : Treasury Yield Hits Multi-Year High 
10/08Perrigo taps Kessler as CEO amid consumer shift